Back to results
US 2022/0064178 A1Published application
Pyridine derivatives
AssigneeHoffmann-La Roche Inc.
InventorsBeat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
Life of this patent
Estimating the term…
Abstract
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
Claims17
A compound of formula (I)
- wherein
- R1 is halophenyl, cycloalkylalkoxy, alkyloxetanylalkoxy, alkoxycarbonylpyrrolidinylalkoxy, alkoxycarbonylpyrrolidinyloxy, alkyl sulfonylphenylalkoxy, haloalkoxy, (alkyl)(halo)cycloalkylalkoxy, benzotriazolyloxy, halopyridinylalkoxy or halopyridinyl;
- R2 is halogen, cycloalkyl, haloalkyl, cycloalkylalkoxy, 2-oxa-6-azaspiro[3.3]heptyl or phenylalkoxy;
- R3 is —C(O)—NH—C(R4R5)m(CH2)n—R6 or alkyloxadiazolyl;
- R4 and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, haloalkyl, azetidinyl, cycloalkylalkyl and cycloalkyl;
- R6 is hydroxyl, hydroxycycloalkyl, alkoxycarbonyl, alkoxycycloalkyl, aminocarbonyl, phenyl, alkyl-1,2,4-oxadiazolyl, alkylaminocarbonyl, haloalkyl or alkyl-1,3,4-oxadiazolyl;
- m is 0 or 1;
- and
- n is 0 or 1;
- or a pharmaceutically acceptable salt or ester thereof.
7 more elements
-13. (canceled)
-17. (canceled)
(canceled)
Dependencies are inferred from the claim text.